T1	Claim 1390 1431	Both agents were safe and well tolerated.
T2	Claim 1254 1389	Over an 8-week period, latanoprost 0.005% once daily lowered IOP more than unoprostone 0.15% twice daily in patients with elevated IOP.
T3	Premise 879 1185	The change in the mean +/- SD of the IOPs measured at 8:00 AM, 12 noon, and 4:00 PM was -7.2 +/- 3.2 mm Hg (28%) for latanoprost (25.3 +/- 2.8 mm Hg at baseline to 18.2 +/- 2.8 mm Hg at 8 weeks) and -3.9 +/- 2.6 mm Hg (15%) for unoprostone (25.5 +/- 3.3 mm Hg at baseline to 21.6 +/- 4.0 mm Hg; P <or=.001.
T4	Premise 1186 1253	No serious adverse event related to either medication was reported.
R1	Support Arg1:T4 Arg2:T1	
R2	Support Arg1:T3 Arg2:T2	
